Native Structure-Based Peptides as Potential Protein–Protein Interaction Inhibitors of SARS-CoV-2 Spike Protein and Human ACE2 Receptor

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a positive-strand RNA virus that causes severe syndrome in humans, which now referred to as coronavirus disease 2019 (COVID-19). Since December 2019, the new pathogen has rapidly spread globally, with over 65 million cases reported beginning of 2020, including 1.5 deaths. Unfortunately, currently, there no specific and effective treatment for COVID-19. As SARS-CoV-2 relies on its spike proteins (S) bind host cell-surface receptor angiotensin-converting enzyme-2(ACE2), this interaction proved be responsible entering into cells, it makes an ideal target antiviral drug development. In work, we design three very short peptides based ACE2 sequence/structure fragments, may effectively receptor-binding domain (RBD) S protein may, turn, disrupt important virus-host protein–protein interactions, blocking early steps infection. Two our affinity nanomolar range, have great potential